Loading clinical trials...
Loading clinical trials...
Comparison of Pain Reduction in Chronic Wounds Treated With and Without Autologous Fat Grafting: A Randomized Controlled Trial
Chronic wounds, such as those caused by diabetes, burns, or poor blood circulation, often heal slowly and can cause significant pain, affecting daily life and quality of life. This study aims to evaluate whether autologous fat grafting-a procedure in which a patient's own fat tissue is injected into the wound-can reduce pain and improve healing in chronic wounds compared to standard care without fat grafting. We will enroll 62 adult patients with chronic wounds lasting more than 3 months. Participants will be randomly assigned to two groups: one group will receive fat grafting along with standard wound care, and the other group will receive standard wound care alone. Pain will be measured using a Visual Analog Scale (VAS) over 21 days after treatment. Wound healing and any complications will also be monitored. The results of this study will help determine if autologous fat grafting is an effective and safe method to reduce pain and improve recovery in patients with chronic wounds.
Chronic wounds are a common problem, particularly in patients with diabetes, vascular diseases, or post-traumatic injuries, and are associated with significant pain, delayed healing, and increased healthcare costs. Pain in chronic wounds can be both background and procedural, affecting quality of life and sometimes leading to psychosocial complications. Current treatments include surgical and non-surgical interventions, such as tulle dressings, interactive dressings, skin substitutes, and negative pressure wound therapy. However, these approaches may be costly, require frequent dressing changes, or have limited availability, particularly in lower-middle-income countries. Autologous fat grafting has emerged as a promising technique to promote wound healing due to the high content of stem cells and growth factors in adipose tissue. Recent studies suggest that fat grafting not only accelerates tissue regeneration but may also reduce pain associated with chronic wounds. Limited data exist regarding its efficacy specifically for pain reduction in chronic wounds. This randomized controlled trial will enroll 62 adult patients (ages 20-60) with chronic wounds persisting for more than 3 months and with a baseline mean VAS pain score \>3. Participants will be randomly assigned to one of two groups: Group A (fat grafting plus standard wound care) or Group B (standard wound care alone). Wound cleansing will be performed in both groups using povidone-iodine. In Group A, autologous fat will be harvested using the Coleman technique, processed into nano-fat through sequential filtering and centrifugation, and injected into the wound bed and margins. In Group B, wounds will be managed with standard tulle gauze dressings. Dressings in both groups will be changed every 48-72 hours. Pain will be assessed using the Visual Analog Scale three times daily for 21 days, and the mean daily pain score will be calculated. Wound healing percentage, wound size, and any complications, including infection, will be documented. Rescue analgesia (IV Toradol 0.5 mg/kg) will be provided if the VAS score exceeds 3. Data will be analyzed using SPSS v26, with appropriate statistical tests applied to compare pain reduction and wound healing between groups. The study aims to provide evidence on the effectiveness and safety of autologous fat grafting for reducing pain and improving outcomes in patients with chronic wounds, potentially informing future clinical practice and management strategies for this patient population.
Age
20 - 60 years
Sex
ALL
Healthy Volunteers
No
Start Date
May 1, 2026
Primary Completion Date
May 1, 2026
Completion Date
November 1, 2026
Last Updated
March 18, 2026
62
ESTIMATED participants
Autologous Fat Grafting
PROCEDURE
Standard Wound Care
PROCEDURE
Lead Sponsor
King Edward Medical University
NCT06346132
NCT07482709
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07351968